VERNAL KERATOCONJUNCTIVITIS MARKET ANALYSIS
Key players operating in the global vernal keratoconjuctivities market are focusing on drug approvals, which is anticipated to drive the market growth during the forecast period.
Increasing drug approvals provides the opportunity to provide patients with novel treatment options, which is projected to boost the market growth during the forecast period. For instance, in June 2021, Santen Pharmaceutical Co., Ltd. announced that U.S. Food and Drug Administration (FDA) approved a new drug verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the treatment of vernal keratoconjunctivitis (VKC) in children as well as adults.
Key Players Major players operating in the global vernal keratoconjunctivitis market include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
